J
Jesper F Højen
Researcher at Aarhus University Hospital
Publications - 19
Citations - 879
Jesper F Højen is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Immune system & Viral load. The author has an hindex of 11, co-authored 17 publications receiving 490 citations. Previous affiliations of Jesper F Højen include University of Colorado Denver & Aarhus University.
Papers
More filters
Journal ArticleDOI
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth,Steffen Leth,Mariane H. Schleimann,Mariane H. Schleimann,Sara K. Nissen,Sara K. Nissen,Jesper F Højen,Jesper F Højen,Rikke Olesen,Mette E. Graversen,Mette E. Graversen,Sofie E. Jørgensen,Sofie E. Jørgensen,Anne Sofie Høgh Kølbæk Kjær,Anne Sofie Høgh Kølbæk Kjær,Paul W. Denton,Paul W. Denton,Alejandra Mørk,Maja A. Sommerfelt,Kim Krogsgaard,Lars Østergaard,Lars Østergaard,Thomas A Rasmussen,Martin Tolstrup,Martin Tolstrup,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard +26 more
TL;DR: This in-vivo combinatorial approach provides the first evidence for the feasibility of a combined shock and kill strategy, but also emphasises that further optimisation of this strategy is needed to achieve a sizeable effect on the latent reservoir that will translate into clinically measurable benefits for people living with HIV-1.
Journal ArticleDOI
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Jesper Damsgaard Gunst,Nina Breinholt Stærke,Marie H. Pahus,Lena Hagelskjaer Kristensen,Jacob Bodilsen,Nicolai Lohse,Nicolai Lohse,Lars Skov Dalgaard,Dorthe Brønnum,Ole Fröbert,Bo Langhoff Hønge,Isik Somuncu Johansen,Ida Monrad,Christian Erikstrup,Christian Erikstrup,Regitze Rosendal,Emil Vilstrup,Theis Mariager,Dorthe Gaby Bove,Rasmus Offersen,Shakil Shakar,Sara Cajander,Nis Pedersen Jørgensen,Sajitha S. Sritharan,Peter Breining,Søren Jespersen,Klaus Leth Mortensen,Mads L. Jensen,Lilian Kolte,Giacomo S. Frattari,Carsten Schade Larsen,Merete Storgaard,Lars Peter Nielsen,Lars Peter Nielsen,Martin Tolstrup,Martin Tolstrup,Eva Aggerholm Sædder,Eva Aggerholm Sædder,Lars Østergaard,Lars Østergaard,Hien T. T. Ngo,Morten Hasselstrøm Jensen,Morten Hasselstrøm Jensen,Jesper F Højen,Mads Kjolby,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard +46 more
TL;DR: In this article, the transmembrane protease serine serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Journal ArticleDOI
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
Line K. Vibholm,Line K. Vibholm,Mariane H. Schleimann,Mariane H. Schleimann,Jesper F Højen,Jesper F Højen,Thomas Benfield,Rasmus Offersen,Rasmus Offersen,Katrine Rasmussen,Rikke Olesen,Anders Dige,Anders Dige,Jørgen Agnholt,Jørgen Agnholt,Judith Grau,Maria J. Buzon,Burghardt Wittig,Mathias Lichterfeld,Andreas Petersen,Xutao Deng,Xutao Deng,Mohamed Abdel-Mohsen,Mohamed Abdel-Mohsen,Mohamed Abdel-Mohsen,Satish K. Pillai,Satish K. Pillai,Sofie Rutsaert,Wim Trypsteen,Ward De Spiegelaere,Linos Vandekerchove,Lars Østergaard,Lars Østergaard,Thomas A Rasmussen,Paul W. Denton,Paul W. Denton,Martin Tolstrup,Martin Tolstrup,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard +39 more
TL;DR: TLR9 agonist treatment in HIV infection has a dual potential by increasing HIV-1 transcription and enhancing cytotoxic NK cell activation, both of which are key outcomes in HIV- 1 eradication therapy.
Journal ArticleDOI
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Peter Breining,Anne Lier Frølund,Jesper F Højen,Jesper Damsgaard Gunst,Jesper Damsgaard Gunst,Nina Breinholt Stærke,Nina Breinholt Stærke,Eva Aggerholm Sædder,Eva Aggerholm Sædder,Manuel Cases‐Thomas,Paul Little,Lars Peter Nielsen,Lars Peter Nielsen,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard,Mads Kjolby +15 more
TL;DR: Camostat mesylate, an orally available well‐known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID‐19, and clinical trials are currently ongoing to test whether this well-known drug could be repurposed and utilized to combat the current pandemic.
Journal ArticleDOI
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.
Line K. Vibholm,Stine S F Nielsen,Marie H. Pahus,Giacomo S. Frattari,Rikke Olesen,Rebecca Andersen,Ida Monrad,Anna H. F. Andersen,Michelle M. Thomsen,Christina V. Konrad,Sidsel D. Andersen,Jesper F Højen,Jesper Damsgaard Gunst,Lars Østergaard,Lars Østergaard,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard,Mariane H. Schleimann,Martin Tolstrup,Martin Tolstrup +19 more
TL;DR: In this paper, a cohort study was conducted between April 3rd-July 9th 2020, recruiting COVID-19 recovered individuals that were symptom-free for at least 14 days.